Deoks

At first glance, Merck’s new cancer-drug deal looks like a $2.13 billion bet. Then you notice the upfront payment: $400 million. So what does the other $1.73 billion mean? It is not a second check waiting to be cashed. It is potential future money tied to milestones that may or may not happen. Merck has already closed an exclusive worldwide license for SPR2015, an experimental KRAS G12D drug. But the program is still preclinical, which puts a lot of distance between a promising lab result and a medicine patients can actually use. That gap—not the headline number alone—is the part worth watching. Previous Tech(EN) post: Northern Star Rejected Gold Fields’ A$38.7B Proposal—Why Its Value Moved — another look at the difference between a headline transaction value and what it may mean in practice. Key Takeaways The $2.13 billion figure is the maximum potential total, including a $400 million upfront payment and up to about $1.73 billion in contingent future milestones. Merck...